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Purpose: Animal studies have demonstrated anti-inﬂammatory, and anti-nociceptive properties of
hyperbaric oxygen therapy (HBOT). However, physiological data are scarce in humans. In a recent
experimental study, the authors used the burn injury (BI) model observing a decrease in secondary
hyperalgesia areas (SHA) in the HBOT-group compared to a control-group. Surprisingly, a long-
lasting neuroplasticity effect mitigating the BI-induced SHA-response was seen in the HBOT-
preconditioned group. The objective of the present study, therefore, was to conﬁrm our previous
ﬁndings using an examiner-blinded, block-randomized, controlled, crossover study design.
Patients and methods: Nineteen healthy subjects attended two BI-sessions with an inter-
session interval of ≥28 days. The BIs were induced on the lower legs by a contact thermode
(12.5 cm2, 47C°, 420 s). The subjects were block-randomized to receive HBOT (2.4 ATA,
100% O2, 90 min) or ambient conditions ([AC]; 1 ATA, 21% O2), dividing cohorts equally
into two sequence allocations: HBOT-AC or AC-HBOT. All sensory assessments performed
during baseline, BI, and post-intervention phases were at homologous time points irrespec-
tive of sequence allocation. The primary outcome was SHA, comparing interventions and
sequence allocations.
Results: Data are mean (95% CI). During HBOT-sessions a mitigating effect on SHA was
demonstrated compared to AC-sessions, ie, 18.8 (10.5–27.0) cm2 vs 32.0 (20.1–43.9) cm2
(P=0.021), respectively. In subjects allocated to the sequence AC-HBOT a signiﬁcantly
larger mean difference in SHA in the AC-session vs the HBOT-session was seen 25.0
(5.4–44.7) cm2 (P=0.019). In subjects allocated to the reverse sequence, HBOT-AC, no
difference in SHA between sessions was observed (P=0.55), conﬁrming a preconditioning,
long-lasting (≥28 days) effect of HBOT.
Conclusion: Our data demonstrate that a single HBOT-session compared to control is
associated with both acute and long-lasting mitigating effects on BI-induced SHA, conﬁrm-
ing central anti-inﬂammatory, neuroplasticity effects of hyperbaric oxygen therapy.
Keywords: burns, hyperbaric oxygenation, inﬂammation, pathophysiology, secondary
hyperalgesia
Plain language summary
Following hyperbaric oxygen therapy in animals, studies demonstrate anti-inﬂammatory and
analgesic effects. However, human studies are surprisingly scarce in this ﬁeld. The authors in
a recent novel study showed that hyperbaric oxygen therapy in humans was associated with a
long-lasting reduction of pain sensitivity in the skin surrounding an injured area. The
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objective of the present study was to further examine and vali-
date these ﬁndings using an improved methodological design. An
experimental ﬁrst degree burn injury was induced on the lower
leg in 19 healthy male subjects followed by an intervention of
either hyperbaric oxygen therapy (2.4 ATA, 100% oxygen, 90
min) or normal ambient conditions (1 ATA, 21% oxygen [corre-
sponds to conditions at sea level]) serving as a control.
Quantitative sensory skin assessments were made at standardized
time intervals. The test subjects received each treatment at study
sessions separated by ≥28 days. The hyperbaric session was
compared to the ambient control session allowing the subjects
to be their own control. Data from the present study conﬁrms our
previous ﬁndings showing a long-lasting (≥1 month) reduction of
pain sensitivity in the skin around the burn injury. These ﬁndings
indicate that hyperbaric oxygen therapy could be an interesting
venue for clinical pain research in persistent postsurgical pain
and phantom limb pain.
Introduction
Hyperbaric oxygen therapy (HBOT) is a recognized treat-
ment form1,2 and has been considered an adjunctive treat-
ment for chronic pain conditions.3,4 Several experimental
studies, using different methods and treatment dosages,
have shown anti-inﬂammatory effects of HBOT,5–7 but
there is a paucity of studies investigating these effects in
humans. A previous study,8 carried out by the present
authors, was the ﬁrst in humans to demonstrate an ameli-
orating effect of HBOT on the pathophysiological conse-
quences following a previously validated inﬂammatory
burn injury (BI) model.9–11 We demonstrated an attenua-
tion of secondary hyperalgesia areas (SHA) in normal skin
surrounding the injury, likely reﬂecting a central anti-noci-
ceptive effect. Interestingly, a preconditioning, protective
effect of HBOT on the development of secondary hyper-
algesia was also seen, more than one month after the
primary injury. Both phenomena indicated an effect on
central sensitization.12,13
The original study was a randomized, controlled, cross-
over study with an open therapeutic design.8 The objective
of the present study was to replicate our ﬁndings, adding
an improved single-blinded design, ie, blinding for exam-
iner bias. The primary outcome was an assessment of
SHA, a measure of central sensitization. The secondary
outcomes were measures of peripheral inﬂammation and
sensitization, ie edema, erythema, mechanical pain thresh-
olds, and, thermal detection and pain thresholds. In addi-
tion, exploratory analyses of the combined data of the
previous and present studies were made.
Methods
Approvals
The study was approved by the Committee of Health
Research Ethics of the Capital Region of Denmark (no.
H-6–2014-089), the Danish Data Protection Agency (no.
30–1332) and the Danish Health Authority (no. 2014–
003858-14). The study was registered before patient
enrollment at EudraCT (no. 2014–003858-14, https://
www.clinicaltrialsregister.eu/ctr-search/search?query=
2014-003858-14), principal investigator: Ole
Hyldegaard, registration date: September 23rd 2014.
The study was also registered in clinicaltrials.gov (clin-
icaltrials.gov identiﬁer: NCT02397343, https://clinical
t r i a l s . g o v / c t 2 / s h o w / N C T 0 2 3 9 7 3 4 3 ? t e r m =
NCT02397343&rank=1). The study complied with reg-
ulations of Good Clinical Practice (GCP) and was mon-
itored by the GCP-unit of Copenhagen University
Hospitals. The manuscript adheres to the applicable
CONSORT guidelines (Figure 1). No amendment to
the original protocol was submitted.
Study design
A randomized (1:1 block allocation), controlled, crossover,
single-blinded design was used. Details are in
Supplemental Document 1, Supplemental Figure 1,
Supplemental Table 1 and Supplemental Video 1. The
subjects were randomized to hyperbaric oxygen treatment
(HBOT: 2.4 ATA, 90 min, no air-breaks) or treatment in an
open environment during ambient pressure conditions
(ambient pressure conditions [AC]: 1 ATA).
Subjects
Subjects were recruited using www.forsoegsperson.dk.
For inclusion and exclusion criteria see Supplemental
Table 2. Before inclusion, the subjects received written
and oral study information and provided informed written
consent. A physical health examination including the
completion of a Professional Association of Diving
Instructors (PADI) health declaration was performed by
a senior medical specialist in diving- and hyperbaric
medicine (OH).
All treatment sessions were made at the Hyperbaric
Unit, Department of Anesthesia, Head and Orthopedic
Center, Rigshospitalet, Copenhagen University Hospitals.
The subjects received a compensation of USD 316 (EUR
268) after completion of both sessions.
Wahl et al Dovepress
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Study algorithm
The study included two sessions, identical except for the type
of intervention treatment (Figure 2A). Each session started
with baseline measurements, in chronological order, skin-
erythema (SE) and dermal-thickness (DT), and, assessments
of quantitative sensory testing (QST) variables: mechanical
thresholds and thermal thresholds. Baseline assessments were
followed by a standardized ﬁrst-degree BI.14,15 Following the
intervention treatment (HBOT/AC) assessments were
repeated at timepoints 130, 190 and 250 min (Figure 2A).
The two sessions were separated by an interval of ≥28 days to
minimize the risk of carry-over effects from the previous BI.
Randomization procedure
Two randomizations were made using www.randomizer.
org. The ﬁrst randomization decided the order of treat-
ment. Subjects were separated into the two sequences; one
sequence starting with the HBOT-session and one starting
with the AC-session (Sequence 1: HBOT1-AC1 sequence;
Sequence 2: AC2-HBOT2 sequence; Figure 2B), dividing
the study into sessions and sequences. The second rando-
mization decided upon the left- or right-sided location of
the ﬁrst of the two BIs.
Randomization allocations and master randomization
lists were kept concealed in opaque envelopes marked
with consecutive numbers. Randomization procedures
were conducted by a medical staff member, otherwise
not associated with this study. The sealed envelopes were
opened, when appropriate by the unblinded co-examina-
tors (DB, ISN) and allocation instructions were followed.
Hyperbaric oxygen therapy procedure
The HBOT procedure was performed as previously
reported in detail.8 The procedure consisted of an initial
Assessed for eligibility (n=39)
Randomized (n=26)
Excluded (n=13)
•   Not meeting inclusion criteria (n=4)
•   Declined to participate (n=9)
•   Other reasons (n=0)
Allocated to intervention HBOT1-AC1 (n=13)
•  Received allocated intervention (n=12)
•  Did not receive allocated intervention
       (dropout before intervention HBOT1) (n=1)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Analysed (n=12)
•  Excluded from analysis (n=0)
Analysed (n=9)
•  Excluded from analysis (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Allocated to intervention AC2+HBOT2 (n=13)
•  Received allocated intervention (n=9)
•  Did not receive allocated intervention
       (dropout before intervention AC2) (n=3)
       (dropout before intervention HBOT2) (n=1)
Enrollment
Allocation
Follow-Up
Analysis
Figure 1 CONSORT ﬂow diagram showing the algorithm for enrollment and allocation of subjects.
Notes: The intention-to-treat (ITT) number was 26, and the per-protocol (PP) number was 19 subjects.
Abbreviations: AC, ambient pressure conditions; HBOT, hyperbaric oxygen therapy.
Dovepress Wahl et al
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compression period lasting 5 min (Figure 2A), reaching a
plateau of 2.4 ATA during which HBOT was administered
for 90 min (100% O2) using no air-breaks, followed by a
short decompression period (Figure 2A).
Sensitization method
The BIs were induced by the co-examinator using a
Peltier-based contact thermode (active area 2.5×5.0 cm2,
47°C, 420 s; Thermotest, MSA, Somedic AB, Hörby,
Sweden). The thermode was positioned at a prespeciﬁed
site on the calf, using the homologous anatomical site on
the contralateral side during the second session. An elastic
compression bandage kept the thermode in position main-
taining a constant application pressure during all assess-
ments. The subject rated the intensity of pain, using a
horizontally held, visual analog scale (VAS; 0= no pain,
10= worst imaginable pain) at baseline, and, at timepoints
0, and 15, 30, 45, 60, 120, 180, 240, 300, 419 and 425 s
after the thermode had reached 47°C.
Measurements and assessments
Skin-erythema and dermal-thickness
Measurements of SE and DTwere made inside and outside
the testing area (10 cm distal from the center) using a
combined non-invasive, skin-reﬂectance spectrophot-
ometer and a high-resolution ultrasound scanner (Derma-
Lab Combo, Cortex Technology ApS, Hadsund,
Denmark).16,17 The spectrophotometer was calibrated
prior to all assessments. The SE was measured as the
erythema index (arbitrary units), and the DT was measured
in the testing area as previously described.15
Measurements were each made in triplicates using the
mean value in further analysis.
Mechanical thresholds
Assessments of pin-prick pain threshold (PPT) were made in
the testing area using “weighted-pins” (8, 16, 32, 64, 128, 256
and 512 mN; MRC Systems, Heidelberg, Germany) accord-
ing to a modiﬁed Dixon’s “up-and-down method”,18–20 as
Figure 2 (A and B) Study setup.
Notes: (A) Study algorithm. Each session followed the same study algorithm except for type of intervention: baseline assessments (0–20 min); burn injury (20–30 min);
HBOT-/AC-intervention (30–130 min); and PI1-3 including measurements of skin-erythema (SE) and dermal-thickness (DT), and QST assessments, mechanical and thermal
thresholds (130–150 min, 190–210 min, 250–270 min). HBOT-intervention included a compression phase (C; 30–35 min); a therapy phase of 100% O2; 2.4 ATA (35–
125 min); and a decompression phase (125–130 min). AC-intervention included control-therapy with 21% O2, 1.0 ATA (30–130 min). Each subject received both treatments
during two individual sessions but was randomized to either HBOT1-AC1 or AC2-HBOT2 sequence (Figure 2B). (B) Sequences, Sessions, and within-/between-sequence
comparisons. Subject-ﬂows were divided into "sequences" (Sequence 1: HBOT1+ AC1; Sequence 2: AC2+ HBOT2) and "sessions" (Session 1: HBOT1+ AC2; Session 2: AC1
+ HBOT2). Within-sequence comparisons are comparisons of data within the same sequence (green lines) (HBOT1 vs AC1; AC2 vs HBOT2) whereas the between-
sequence comparisons are comparisons of data between sequences (red lines) (HBOT1 vs HBOT2; AC1 vs AC2).
Abbreviations: AC, ambient pressure conditions; HBOT, hyperbaric oxygen therapy; PI, post-injury; QST, quantitative sensory testing.
Wahl et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
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previously reported.8 The PPT was determined four times,
and the median value was used in further analysis.
Secondary hyperalgesia areas
Assessment of the SHA was by a 512 mN “weighted-pin”
stimulator.19 The area surrounding the BI was stimulated
clockwise along eight symmetrical radials converging
towards the center of the BI, as previously reported.8 The
stimulation began in normal skin with an application rate of
0.5 Hz and a distance of 1–2 cm between each pin-prick,
projecting in towards the center. The subject indicated when
a deﬁnite change in perception, from a non-noxious to an
uncomfortable or stinging sensation occurred. The octago-
nal corners of secondary hyperalgesia were marked on the
skin. The markings were then transferred by manual copy-
ing onto a transparent overhead sheet and digitally trans-
ferred to a vector-based computer program (Canvas 8.0,
ACD Systems International, Victoria, Canada) for area cal-
culations. The SHAwere calculated by subtracting the test-
ing area from the total area.
Thermal Thresholds
Warmth detection threshold (WDT), cool detection thresh-
old (CDT) and heat pain threshold (HPT) were assessed
using the contact thermode system and determined accord-
ing to the-method-of-limits,21 as previously reported.8
Threshold assessments were made in triplicate using the
mean value in further analysis.
Statistics
Statistical analyses
Data were manually checked for errors by one of the
investigators (AW) and by the GCP-unit. Statistical ana-
lyses were made using the MedCalc Statistical Software
(Version 15.11.4, MedCalc Software bvba, Ostend,
Belgium). During the statistical analyses, data were ﬁrst
partially unblinded dividing the subjects into two groups,
A and B. Data were unblinded only after completion of the
analysis. Normality of the data was tested using the
Kolmogorov-Smirnov test and visual inspection of resi-
dual plots. When relevant, data were corrected with base-
line values obtained at the beginning of each session to
avoid potential carryover effects between the two sessions.
To avoid mass signiﬁcance in multiple comparisons, a
summated AUC-measure (area-under-the-curve min−1)
was used where appropriate. For normally distributed
data, signiﬁcance was determined using the paired or
unpaired t-tests, and for non-normally distributed data the
Wilcoxon or Mann-Whitney tests, respectively, were used
as appropriately. Comparisons across sessions and
sequences were made to explore potential preconditioning
effects (Figure 2B). In analysis of the consistency of base-
line assessments, intraclass correlation coefﬁcients (ICC
[2,1; two-way random single measures, consistency]) were
used, categorized as previously reported.22 Depending on
normality, data are presented as mean or median (95% CI).
The level of statistical signiﬁcance was a priori set at
<0.05. The Bonferroni correction was used for multiple
comparisons for the primary outcome, the statistical sig-
niﬁcance therefore was set at 0.025.
Sample size estimates
Based on the primary outcome, SHA, and the results from
our original study,8 an a priori sample size estimation was
made using a minimal relevant difference of 19 cm2 and a
standard deviation of 28 cm2. The signiﬁcance level was
set at 0.05 (α) and the power at 0.8 (β=0.2). A randomized,
single-blinded, crossover design was used. The calcula-
tions yielded an estimated sample size of 19 per-protocol
subjects, but to compensate for dropouts the number of
intention-to-treat subjects was 26.
Exploratory analyses of combined data
Exploratory analyses were made by combined data from
the present study with data from our original study.8
Statistical analyses were made using the same methods
as described in the previous paragraph.
Results
Subjects
Subject ﬂow
The ﬁrst study session was on February 16, 2015, and the last
study session was on May 13, 2015. The study was com-
pleted when the a priori estimated sample size had been
reached. Twenty-six subjects were included in the study
following the initial visit, however, ﬁve subjects did not
complete the study (Figure 1; CONSORT 2010 Flow
Diagram). Two subjects (#3, #6) never showed up after the
initial visit. One subject (#26) decided, due to time restraints,
not to take part in the study. One subject (#13) had to with-
draw before the intervention, due to medical reasons not
associated with the study. One subject (#1) never showed
up at the second study session (HBOT2-session). Data from
these ﬁve subjects were not included in the statistical ana-
lyses. Thus, 21 subjects completed the trial. No adverse
effects or complications were seen during the study.
Dovepress Wahl et al
Journal of Pain Research 2019:12 submit your manuscript | www.dovepress.com
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Missing data
Data sets from these 21 subjects were incomplete for
subjects #10, #16 and #25. Subjects #10 and #16 were
unable to consistently perceive secondary hyperalgesia,
and their SHA-assessments were excluded from the ana-
lysis, leaving 19 data sets available for the primary out-
come analysis. Subject #25 presented an incomplete data
set regarding SE-measurements, leaving 20 data sets for
analysis of SE-data (n=20). The missing SE-data were
attributed to human error, constituting only 4/3,864
(0.1%) of the total number of data entries.
Anthropometrics
Anthropometrics are shown in Table 1.38
Burn injury
The median time interval between the two BIs (sessions)
was 35 days (34–39 days). The mean pain intensity during
the BIs, calculated as AUC, was 3.3 (2.4–4.1) VAS-units
during the AC-sessions, and 3.0 (2.3–3.6) VAS-units dur-
ing the HBOT-sessions (P=0.59).
Primary outcome (secondary hyperalgesia
areas)
Baseline data
Data consistency during Session 1 vs Session 2
(Figure 2B) was examined by ICC’s (0.85 [0.64–0.94])
and by comparisons of baseline assessments using sim-
ple paired sample tests demonstrating a highly signiﬁ-
cant difference in baseline assessments between the
sessions (Wilcoxon: P=0.0017). The median values for
SHA were signiﬁcantly larger in Session 1 (26.6 [12.5–
37.6] cm2) compared to Session 2 (15.9 [12.5–
23.4] cm2).
Post-injury vs baseline assessments
Data consistency of BI-induced changes in sensory
assessments were examined by comparisons between
baseline and post-injury 1–3 (PI1-3) AUC-values.
Signiﬁcantly increased BI-induced SHA-values were
seen in both sessions (HBOT-session, P=0.0002; AC-
session, P=0.0001).
HBOT vs AC-sessions: SHA-values of the HBOT-
and AC-sessions, respectively, were calculated as AUC
corrected for the respective baseline values and given as
the mean. HBOT-sessions showed a SHA of 18.8 (10.5–
27.0) cm2, whereas the AC-sessions had an area of 32.0
(20.1–43.9) cm2 (P=0.021; Figure 3A), indicating a sig-
niﬁcant mitigating effect of HBOT-sessions compared to
AC-sessions.
Within-sequence and between-sequence effects
Within-sequence effects were examined, in Sequence 1 com-
paring session HBOT1with session AC1, and, in Sequence 2
comparing session AC2 with session HBOT2 (Figure 2B).
The comparison in Sequence 1 (HBOT1 vs AC1; Figure 4A)
did not yield any statistical difference (P=0.55) while in
Sequence 2 (AC2 vs HBOT2), a signiﬁcantly larger area in
the AC2-session was demonstrated, corresponding to a mean
difference of 25.0 (5.4–44.7) cm2, compared to the HBOT2-
session (P=0.019).
Between-sequence effects were examined by comparing
session HBOT1 with session HBOT2, and, by comparing
session AC1 with session AC2 (Figure 2B). While the com-
parison of HBOT-sessions did not yield any statistical sig-
niﬁcance (P=0.73), comparison of the AC-sessions
demonstrated a statistically signiﬁcant larger area in the
AC2-session, corresponding to a mean difference of 25.5
(4.9–46.1) cm2, compared to the AC1-session (P=0.018).
Summary
The analyses demonstrated a mitigating effect on SHA of
HBOT-sessions vis-á-vis AC-sessions. Furthermore, they
demonstrated a signiﬁcant preconditioning effect in
Sequence 1 when the HBOT-session was administered
prior to the AC-session, compared to Sequence 2, when
the AC-session preceded the HBOT-session (Figure 2B).
Secondary outcomes (SE, DT, mechanical
and thermal thresholds)
Baseline data
Data consistency for secondary outcomes are available in
Supplemental Document 2.
Table 1 Anthropometric data
ITT; n=21 PP; n=19
Height (cm) 183.2 (179.5–186.9) 183.5 (179.5–187.6
Weight (kg) 79.8 (74.6–84.9) 79.2 (73.6–84.8)
Age (yr)a 26.1 (24.9–29.5) 26.1 (24.7–28.8)
BSA (m2) 2.01 (1.93–2.09) 2.01 (1.92–2.09)
BMI (kg/m2) 23.7 (22.5–24.9) 23.5 (22.2–24.7)
Notes: Data are normally distributed (mean [95% CI]), except for age a(median
[95% CI]).
Abbreviations: ITT, intention-to-treat; PP, per-protocol; BMI: body mass index;
BSA: body surface area.
Wahl et al Dovepress
submit your manuscript | www.dovepress.com
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Post-injury vs baseline assessments
Comparisons between baseline values and post-injury
values are available in Supplemental Document 2.
HBOT vs AC-sessions
No statistically signiﬁcant differences between sessions,
calculated as AUC corrected for the respective baseline
values, were found regarding the mean values in SE, DT,
PPT or the median values in CDT. A signiﬁcantly lower
mean WDT was found in the HBOT-session compared to
the AC-session (P=0.011). A signiﬁcantly lower mean
value was also found regarding HPT in the HBOT-session,
compared to the AC-session (P=0.045). For detailed sec-
ondary outcome analyses see Supplemental Document 2.
Figure 3 (A and B) Changes in secondary hyperalgesia areas.
Notes: (A) Present study (n=19). Dot-line diagram illustrating the individual subject’s changes in secondary hyperalgesia areas (SHA) during ambient pressure conditions
sessions (AC) and hyperbaric oxygen therapy sessions (HBOT). The mean values of AC- and HBOT-sessions were 32.0 cm2 (20.1–43.9 cm2) and 18.8 (10.5–27.0 cm2;
paired t-test: P=0.021), respectively, indicated by red lines. SHA-values are baseline corrected, calculated as AUC and presented as cm2. Negative values are results of
corrections with baseline values in two subjects perceiving a baseline, pre-burn SHA (cf. "Protocol violations"). (B) Combined data (n=36). Dot-line diagram illustrating
the combined data. The mean values of AC- and HBOT-sessions were 40.9 cm2 (31.8–50.0 cm2) and 26.4 (19.7–33.0 cm2; paired t-test: P=0.0018), respectively, indicated
by a red line.
Abbreviations: AC, ambient pressure conditions; HBOT, hyperbaric oxygen therapy; SHA, Secondary hyperalgesia areas.
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Figure 4 (A and B) Protective, preconditioning effect of hyperbaric oxygen therapy on secondary hyperalgesia areas.
Notes: (A) Present study (n=19). Box-plots of secondary hyperalgesia areas (SHA; mean [95% CI]) during Sequence 1 (HBOT1-AC1) and Sequence 2 (AC2-HBOT2). The
SHA are baseline corrected, calculated as AUC and presented as cm2. A signiﬁcant difference between the HBOT- and AC-sessions was seen in Sequence 2 (P=0.019),
indicating a preconditioning effect of HBOT. No difference was seen between the HBOT- and AC-sessions in Sequence 1 (P=0.56). (B) Combined data (n=36). A signiﬁcant
difference between the HBOT- and AC-sessions was seen in Sequence 2 (P=0.0001), indicating a preconditioning effect of HBOT. No difference was seen between the HBOT-
and AC-sessions in Sequence 1 (P=0.55). Data were compared using the paired t-test.
Abbreviations: AC, ambient pressure condition sessions; AUC, area-under-the-curve; HBOT, hyperbaric oxygen therapy session; SHA, Secondary hyperalgesia
areas.
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Combined primary outcome data from
original and present study
Subjects
Nineteen subjects were included from the present study
and 17 subjects from the original study,8 making a total of
36 subjects available for the combined data analysis.
Baseline data
The original study showed no baseline SHA and, there-
fore, the combined baseline data are identical to results of
the present study.
Post-injury vs baseline assessments
Signiﬁcantly increased BI-induced SHA-values were seen in
both sessions (HBOT-session and AC-session, P=0.0001).
HBOT vs AC-sessions
Signiﬁcantly smaller mean SHAwere found in the HBOT-
group (26.4 [19.7–33.0]: Figure 3B) compared to the AC-
group (40.9 [31.8–50.0]: P=0.0018), corroborating a miti-
gating effect of HBOT.
Within-sequence and between-sequence effects
Within-sequence effects showed no statistical differ-
ence in Sequence 1 (HBOT1 vs AC1; Figure 4B)
(P=0.96) while signiﬁcantly larger SHA were found in
the AC2-session compared to the HBOT2-session, cor-
responding to a mean difference of 30.5 cm2 (17.9–
43.2 cm2; P=0.0001).
Between-sequence effects comparing the HBOT-ses-
sions (HBOT1 vs HBOT2; Figure 4B) did not yield any
statistical difference (P=0.47). However, a signiﬁcant dif-
ference was found when comparing the AC-sessions (AC1
vs AC2) showing a statistically signiﬁcantly larger area in
the AC2-session, corresponding to a mean difference of
29.7 cm2 (14.9–44.4 cm2; P=0.0006), compared to the
AC1-session, corroborating the preconditioning effect of
the HBOT1-session.
Summary
The analyses of the combined data demonstrated ﬁrst, a
highly signiﬁcant decrease in SHA related to HBOT
compared to AC (P=0.0018). Second, a highly signiﬁ-
cant preconditioning effect on the development of SHA
related to HBOT (P=0.0001). Third, the combined
study results corroborated the data consistency between
the studies.
Protocol violations
During data collection, the examiner noticed a number of
baseline pre-burn SHA. However, according to our experi-
ence, this is rarely observed in healthy skin, and therefore
a short questionnaire was made to evaluate if the subjects
were, in fact, able to detect SHA. Most subjects were able
to discriminate secondary hyperalgesia from normal sensa-
tion. However, two subjects (#10, #16) were not able to
discriminate or could not recall a perceptual difference
between pre- and post-burn SHA and were therefore
excluded in the data analysis of SHA (cf. Missing data).
The implementation of the questionnaire had not been
described in the protocol and is, therefore, a minor viola-
tion of protocol.
Discussion
In the human experimental BI-model, we demonstrated
that HBOT mitigates inﬂammation-induced secondary
hyperalgesia. Remarkably, a single session of HBOT also
has a preconditioning, long-lasting, pre-emptive anti-
hyperalgesic effect on a contralateral repeat injury. Since
no signs of mitigation of the primary hyperalgesia in the
injured areas were found, our data clearly demonstrate that
HBOT has acute and long-lasting neuroplasticity effects
on central sensitization.23,24
Mitigation of secondary hyperalgesia
Secondary hyperalgesia is a centrally induced
phenomenon12,13,23 where the conditioning input from
nociceptors by heterosynaptic potentiation ampliﬁes the
response from segmentally connected afferent non-noci-
ceptive and nociceptive nerve ﬁbers. Although the clinical
role of central sensitization has been debated,23,25 it may
contribute to the pain trajectories of osteoarthritis, tempor-
omandibular joint disorders, neuropathic pain, visceral
pain hypersensitivity disorders and persistent post-surgical
pain.12 Neuroplasticity represents a physiological adaption
in the nervous system responding to perturbations in the
external environment.26,27 Neuroplasticity leads to func-
tional and structural alterations in the nervous system and
is intimately linked to memory processing, storage and
consolidation. In the nociceptive system, modulation of
ascending and descending control pathways are by neuro-
plasticity mechanisms.28 In humans central sensitization of
pain, eg, secondary hyperalgesia, temporal summation,
and long term potentiation,12,29 is often coined a
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maladaptive neuroplasticity response, mainly affecting the
descending inhibition system.27,28 The available evidence
from this study, therefore, substantiate the presence of a
potential neuroplasticity mechanism in the phenotypic
changes: the mitigation of secondary hyperalgesia.
However, it would be interesting to obtain further proof
of neuronal plasticity with MRI using the BOLD-
technique.30
Interestingly, the time frame of neuroplasticity changes in
pain phenotype is neatly demonstrated in the present study.
The acute mitigating effect on injury induced SHA is seen
hours after the injury while the preemptive, protective effect
on development of SHA is demonstrated four weeks follow-
ing preconditioning with a single session HBOT. Recent
clinical studies indicate that HBOT attenuates chronic pain
in ﬁbromyalgia by inducing neuroplasticity following a ser-
ies of 40 treatment sessions, thereby rectifying abnormal
brain activity in pain related areas.3 One animal study
found a two-phase antinociceptive effect, with the second
phase lasting up to three weeks after four HBOT-sessions by
a mechanism mediated through the NO dependent release of
endogenous opiods.31 As pain disorders are not congenital
but evolve over time due to multifactorial causes, the concept
of neuroplasticity is inherent in the development of pain
disorders. Since HBOT has been shown to induce neuroplas-
ticity in the chronically injured brain even months to years
after the acute insult,3,32 understanding the speciﬁc mitigat-
ing mechanisms of HBOT on the pathophysiological pertur-
bations following tissue injury may shed some light on future
management strategies as well as indicating rational and
targeted use of HBOT33 in various pain disorders.
Effects of HBOT on the primary burn
injury area
Areduction inWDTandHPTin theHBOT-sessions compared
to the AC-sessions was demonstrated, but no other signiﬁcant
differences in QST-indices in the primary BI-area were found.
Multiple comparisons were made in the secondary analysis
without using Bonferroni correction, leaving a considerable
risk of type 1 error. Therefore, our results hardly support any
effect of HBOTon the primary BI-area.
Combined data from original and present
study
Methodological differences
We decided to combine the data of the present study with
data from our original study8 in order to cautiously examine
the statistical consistency of the studies. The two studies are
methodologically almost identical, but few important differ-
ences do exist. First, the roles of examiner and co-exam-
inator, and, the blinding procedure, are novel in the present
study. Second, the delineating-method of SHA using pin-
prick instruments vs polyamide monoﬁlaments in the origi-
nal study differed. However, this unlikely inﬂuences the
results, since we used paired data analysis with each subject
being his control and furthermore, it has been demonstrated
that the results obtained by the two delineating-methods are
reproducible and inter-correlated.19 We, therefore, consider
combining the results to be appropriate and methodologi-
cally interesting.
Mitigation of secondary hyperalgesia and
preconditioning
When combining the data, the results had the same general
tendency as in the individual studies, but with a markedly
increased statistical signiﬁcance. Although the interpreta-
tion of post-hoc analyses should be made with diligence
the effect sizes of the present study and the combined
studies, were very large, 2.5 and 3.5, respectively. The
statistical signiﬁcance increased with P-values from
0.021 (n=19) to 0.0018 (n=36), making a type I error
very unlikely.
Data consistency
In the present study and the combined studies, we found a
statistically signiﬁcant difference in SHA baseline values
between Session 1 and Session 2, probably indicating a
habituation phenomenon. However, this does not affect
our results, since corrections with baseline values have
been made. The ICC’s showed excellent data consistency.
Limitations of the study
Blinding conditions
During this single-blinded, block-randomized, controlled,
crossover study, the examiner was blinded to the subject’s
allocation, but the design did not prevent the development
of subject bias. While it is highly unlikely that the subject
could consciously replicate the preconditioning effects
with the sparse information received in combination with
the randomization- and group allocation procedures per-
formed (Figure 2B), we cannot exclude subject bias.
Double-blind designs have been reported to be feasible
in a hyperbaric environment.1,34,35 However, to do this, a
single-seat hyperbaric chamber would be needed or, alter-
natively, a study design with seven participants receiving
treatment simultaneously requiring a huge number of
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examiners and co-examiners to do the assessments.
Unfortunately, neither of these setup designs were possible
during the present study.
Multiple comparisons
Multiple comparisons were made in the statistical sub-ana-
lyses of the primary outcome increasing the likelihood of
introducing a type 1 error. In spite of the conservative
Bonferroni correction, the results continued to be statistically
signiﬁcant in the present study and the combined analyses,
indicating that a type 1 error would be highly unlikely.
Advantages of the study
Growing concerns about the reproducibility in scientiﬁc
research has been expressed during the last decade.36,37 In
the previous study the small number of subjects and the
single-session procedure seemed potential confounding
factors. Our principal objective of the present study was
to replicate and validate our previous study results on the
effect of HBOT on human burn pathophysiology.
Conclusion
The present study demonstrates that hyperbaric oxygen
therapy has an immediate mitigating effect, as well as a
long-lasting preconditioning effect, on secondary hyperal-
gesia induced by a repeat burn injury. These are the ﬁrst
studies in humans to demonstrate ameliorating effects of
hyperbaric oxygen therapy on central sensitization, and the
results corroborate experimental ﬁndings from animal stu-
dies. Hyperbaric oxygen therapy seems an interesting
venue for future preventive measures in severe pain con-
ditions characterized by central sensitization, eg, persistent
postsurgical pain and phantom limb pain.
Abbreviation list
AC, ambient conditions; AUC, area-under-the-curve per
minute; BI, burn injury; CDT, cool detection threshold;
DT, dermal-thickness; HBOT, hyperbaric oxygen therapy;
HPT, heat pain threshold; ICC, intraclass correlation coef-
ﬁcients; PADI, Professional Association of Diving
Instructors; PPT, pin-prick pain threshold; SE, skin-
erythema; SHA, secondary hyperalgesia areas; WDT,
warmth detection threshold.
Data availability
The complete dataset is available in Supplemental File 1.
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